News & Videos - IMMUNOVIA AB - English

The exercise period for warrants of series TO 2 beings today: Immunovia AB PR Newswire LUND, Sweden, Jan. 2, 2025 LUND, Sweden , Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025 . Summarized terms for the warrants of series TO 2 Structure :...

The exercise period for warrants of series TO 2 beings today: Immunovia AB PR Newswire LUND, Sweden, Jan. 2, 2025 LUND, Sweden , Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025 . Summarized terms for the warrants of series TO 2 Structure :...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND, Sweden, Dec. 28, 2024 LUND, Sweden , Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46 . The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025 . The last...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND, Sweden, Dec. 28, 2024 LUND, Sweden , Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46 . The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025 . The last...

Immunovia discovery study published in top protein research journal PR Newswire LUND, Sweden, Dec. 20, 2024 LUND, Sweden , Dec. 20, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research . The study is the largest and most comprehensive pancreatic...

End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding PR Newswire LUND, Sweden, Dec. 19, 2024 LUND, Sweden , Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025. In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success As 2024 began, we had recently completed a significant transformation of the company. We were a much smaller, more...

Immunovia CEO and board members announce intention to fully exercise their TO2 warrants PR Newswire LUND, Sweden, Dec. 18, 2024 LUND, Sweden , Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company's rights issue that was announced on May 20, 2024 . Immunovia CEO Jeff Borcherding , one of the company's largest shareholders based on...

Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, Dec. 16, 2024 LUND, Sweden , Dec. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024 . As a follow up, Immunovia will host a webcast on Tuesday,...

Immunovia announces financial calendar for financial year 2025/2026 PR Newswire LUND, Sweden, Dec. 11, 2024 LUND, Sweden , Dec. 11, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026. Year-End 2024 Report February 25 , 2025 Q1 Report, 2025 May 14 , 2025 Q2 Report, 2025 August 21 , 2025 Q3 Report, 2025 November 19, 2025 Year-End 2025 Report...

Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer PR Newswire LUND, Sweden, Dec. 9, 2024 LUND, Sweden , Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC). In the...

Immunovia to present at the Redeye Technology & Life Science Day PR Newswire LUND, Sweden, Nov. 28, 2024 LUND, Sweden , Nov. 28, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV) , the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3 , hosted by Redeye. Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking work of these companies. During the event, Immunovia...

Immunovia Publishes Interim Report for January-September 2024 PR Newswire LUND, Sweden, Nov. 27, 2024 LUND, Sweden , Nov. 27, 2024 /PRNewswire/ -- July- September 2024 Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488). Net earnings amounted to -51.1 MSEK (-38.6). Earnings per share before and after dilution were -0.73 SEK (-0.91). Cash flow from operating activities amounted to -21.2 MSEK (-35.6). Cash and cash equivalents at end of period amounted to 54.2 MSEK...

Immunovia Publishes Interim Report for January-September 2024 PR Newswire LUND, Sweden, Nov. 27, 2024 LUND, Sweden , Nov. 27, 2024 /PRNewswire/ -- July- September 2024 Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488). Net earnings amounted to -51.1 MSEK (-38.6). Earnings per share before and after dilution were -0.73 SEK (-0.91). Cash flow from operating activities amounted to -21.2 MSEK (-35.6). Cash and cash equivalents at end of period amounted to 54.2 MSEK...

Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas--Inherited Gastrointestinal Cancers PR Newswire PHILADELPHIA, Nov. 15, 2024 PHILADELPHIA , Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company's next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited...

Invitation to Immunovia's Q3 presentation PR Newswire LUND, Sweden, Nov. 12, 2024 LUND, Sweden , Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET . Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET . The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding , CEO and President, and Karin Almqvist Liwendahl, CFO, will present on...

Invitation to Immunovia's Q3 presentation PR Newswire LUND, Sweden, Nov. 12, 2024 LUND, Sweden , Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET . Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET . The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding , CEO and President, and Karin Almqvist Liwendahl, CFO, will present on...

Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium PR Newswire SAN DIEGO, Nov. 7, 2024 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM : IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic...

Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer PR Newswire LUND, Sweden, Oct. 7, 2024 LUND, Sweden , Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key...

Immunovia completes analytical validation of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, Oct. 2, 2024 LUND, Sweden , Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set of parameters,...

Change in number of shares and votes in Immunovia AB (publ) PR Newswire LUND, Sweden, Sept. 30, 2024 LUND, Sweden , Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to underwriters in the rights issue resolved by the...